Hypertrophy

GH / IGF-1 axis and muscle synthesis signalling.

Focus pathways

01GH release

02IGF-1 axis

03mTORC1 signalling

04Satellite cells

01 / Overview

Hypertrophy research sits at the intersection of growth hormone release and muscle protein synthesis pathways: mTORC1, IGF-1, satellite cell activation and catabolic braking. Secretagogues such as CJC-1295 and Ipamorelin stimulate the pituitary to release GH in its natural pulsatile pattern, preserving endogenous rhythm.

02 / Topics

Mechanisms, models and directions

T · 01R-04

GHRH analogues

CJC-1295 (with or without DAC) is a stabilised GHRH analogue that extends the pituitary GH release window. Studies measure 24-hour GH AUC, steady-state IGF-1, REM sleep windows and lean mass changes.

T · 02R-04

Ghrelin mimetics

Ipamorelin is a selective GHS-R agonist with minimal effect on cortisol or prolactin. It is often paired with a GHRH analogue to stimulate both pathways simultaneously in a research protocol. Focus areas include pre-meal and pre-sleep timing on GH peak amplitude.

T · 03R-04

Satellite cell activation

Follistatin-class molecules and selective myostatin antagonists release the brake on muscle growth, increasing muscle fibre cross-sectional area. Studies watch long-term cardiac morphology and target specificity.

03 / Protocols

Protocol skeletons

Reference only for researchers in compliant settings.

PROTOCOL / 01R-04

GHRH + GHRP combination

CJC-1295 (no DAC) + Ipamorelin

Dose: 100 to 300 μg each, 2 to 3 times daily
Duration: 12 to 16 weeks
Notes: Avoid dosing within 90 minutes of a high-insulin meal. Track IGF-1 and fasting glucose.

PROTOCOL / 02R-04